384 related articles for article (PubMed ID: 15901805)
1. The endocannabinoid noladin ether acts as a full agonist at human CB2 cannabinoid receptors.
Shoemaker JL; Joseph BK; Ruckle MB; Mayeux PR; Prather PL
J Pharmacol Exp Ther; 2005 Aug; 314(2):868-75. PubMed ID: 15901805
[TBL] [Abstract][Full Text] [Related]
2. Agonist-directed trafficking of response by endocannabinoids acting at CB2 receptors.
Shoemaker JL; Ruckle MB; Mayeux PR; Prather PL
J Pharmacol Exp Ther; 2005 Nov; 315(2):828-38. PubMed ID: 16081674
[TBL] [Abstract][Full Text] [Related]
3. Endocannabinoid 2-arachidonyl glycerol is a full agonist through human type 2 cannabinoid receptor: antagonism by anandamide.
Gonsiorek W; Lunn C; Fan X; Narula S; Lundell D; Hipkin RW
Mol Pharmacol; 2000 May; 57(5):1045-50. PubMed ID: 10779390
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors.
Felder CC; Joyce KE; Briley EM; Mansouri J; Mackie K; Blond O; Lai Y; Ma AL; Mitchell RL
Mol Pharmacol; 1995 Sep; 48(3):443-50. PubMed ID: 7565624
[TBL] [Abstract][Full Text] [Related]
5. Tamoxifen Isomers and Metabolites Exhibit Distinct Affinity and Activity at Cannabinoid Receptors: Potential Scaffold for Drug Development.
Ford BM; Franks LN; Radominska-Pandya A; Prather PL
PLoS One; 2016; 11(12):e0167240. PubMed ID: 27936172
[TBL] [Abstract][Full Text] [Related]
6. Sphingosine and its analog, the immunosuppressant 2-amino-2-(2-[4-octylphenyl]ethyl)-1,3-propanediol, interact with the CB1 cannabinoid receptor.
Paugh SW; Cassidy MP; He H; Milstien S; Sim-Selley LJ; Spiegel S; Selley DE
Mol Pharmacol; 2006 Jul; 70(1):41-50. PubMed ID: 16571654
[TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo pharmacology of synthetic olivetol- or resorcinol-derived cannabinoid receptor ligands.
Cascio MG; Bisogno T; Palazzo E; Thomas A; van der Stelt M; Brizzi A; de Novellis V; Marabese I; Ross R; van de Doelen T; Brizzi V; Pertwee R; Maione S; Di Marzo V
Br J Pharmacol; 2006 Oct; 149(4):431-40. PubMed ID: 16953186
[TBL] [Abstract][Full Text] [Related]
8. Noladin ether, a putative endocannabinoid, inhibits mu-opioid receptor activation via CB2 cannabinoid receptors.
Páldyová E; Bereczki E; Sántha M; Wenger T; Borsodi A; Benyhe S
Neurochem Int; 2008 Jan; 52(1-2):321-8. PubMed ID: 17698254
[TBL] [Abstract][Full Text] [Related]
9. Functional Selectivity of CB2 Cannabinoid Receptor Ligands at a Canonical and Noncanonical Pathway.
Dhopeshwarkar A; Mackie K
J Pharmacol Exp Ther; 2016 Aug; 358(2):342-51. PubMed ID: 27194477
[TBL] [Abstract][Full Text] [Related]
10. Activation of the human peripheral cannabinoid receptor results in inhibition of adenylyl cyclase.
Slipetz DM; O'Neill GP; Favreau L; Dufresne C; Gallant M; Gareau Y; Guay D; Labelle M; Metters KM
Mol Pharmacol; 1995 Aug; 48(2):352-61. PubMed ID: 7651369
[TBL] [Abstract][Full Text] [Related]
11. Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656, and AM630.
Ross RA; Brockie HC; Stevenson LA; Murphy VL; Templeton F; Makriyannis A; Pertwee RG
Br J Pharmacol; 1999 Feb; 126(3):665-72. PubMed ID: 10188977
[TBL] [Abstract][Full Text] [Related]
12. Inverse agonist properties of N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2, 4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide HCl (SR141716A) and 1-(2-chlorophenyl)-4-cyano-5-(4-methoxyphenyl)-1H-pyrazole-3-carboxyl ic acid phenylamide (CP-272871) for the CB(1) cannabinoid receptor.
Meschler JP; Kraichely DM; Wilken GH; Howlett AC
Biochem Pharmacol; 2000 Nov; 60(9):1315-23. PubMed ID: 11008125
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological characterization of a novel cannabinoid ligand, MDA19, for treatment of neuropathic pain.
Xu JJ; Diaz P; Astruc-Diaz F; Craig S; Munoz E; Naguib M
Anesth Analg; 2010 Jul; 111(1):99-109. PubMed ID: 20522703
[TBL] [Abstract][Full Text] [Related]
14. Species comparison and pharmacological characterization of rat and human CB2 cannabinoid receptors.
Mukherjee S; Adams M; Whiteaker K; Daza A; Kage K; Cassar S; Meyer M; Yao BB
Eur J Pharmacol; 2004 Nov; 505(1-3):1-9. PubMed ID: 15556131
[TBL] [Abstract][Full Text] [Related]
15. Dual intracellular signaling pathways mediated by the human cannabinoid CB1 receptor.
Calandra B; Portier M; Kernéis A; Delpech M; Carillon C; Le Fur G; Ferrara P; Shire D
Eur J Pharmacol; 1999 Jun; 374(3):445-55. PubMed ID: 10422789
[TBL] [Abstract][Full Text] [Related]
16. The tamoxifen derivative ridaifen-B is a high affinity selective CB
Franks LN; Ford BM; Fujiwara T; Zhao H; Prather PL
Toxicol Appl Pharmacol; 2018 Aug; 353():31-42. PubMed ID: 29906493
[TBL] [Abstract][Full Text] [Related]
17. Characterization of the intrinsic activity for a novel class of cannabinoid receptor ligands: Indole quinuclidine analogs.
Franks LN; Ford BM; Madadi NR; Penthala NR; Crooks PA; Prather PL
Eur J Pharmacol; 2014 Aug; 737():140-8. PubMed ID: 24858620
[TBL] [Abstract][Full Text] [Related]
18. Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro.
Thomas A; Baillie GL; Phillips AM; Razdan RK; Ross RA; Pertwee RG
Br J Pharmacol; 2007 Mar; 150(5):613-23. PubMed ID: 17245363
[TBL] [Abstract][Full Text] [Related]
19. Noladin ether, a putative endocannabinoid, attenuates sensory neurotransmission in the rat isolated mesenteric arterial bed via a non-CB1/CB2 G(i/o) linked receptor.
Duncan M; Millns P; Smart D; Wright JE; Kendall DA; Ralevic V
Br J Pharmacol; 2004 Jun; 142(3):509-18. PubMed ID: 15148262
[TBL] [Abstract][Full Text] [Related]
20. Resorcinol-sn-glycerol derivatives: novel 2-arachidonoylglycerol mimetics endowed with high affinity and selectivity for cannabinoid type 1 receptor.
Brizzi A; Cascio MG; Frosini M; Ligresti A; Aiello F; Biotti I; Brizzi V; Pertwee RG; Corelli F; Di Marzo V
J Med Chem; 2011 Dec; 54(24):8278-88. PubMed ID: 22044209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]